-transparent.png){kind=logo}
The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. Patients refractory to conventional therapy, such as corticosteroid administration, corticosteroid or cyclophosphamide pulse therapy [2 with dermatomyositis (DM), 1 with polymyositis (PM)] were treated with IVIG (0.4 g/kg daily) for 5 days. Clinical improvement was apparent within 1-2 months after IVIG and persisted for 19-23 months (DM patients) and 12 months (PM patient). No adverse effects were observed. Thus, IVIG may be considered an effective therapy for refractory myositis.
Related Publications
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
November 2014,
Pediatrics,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
May 1987,
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
September 2008,
Cornea,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
January 2021,
Actas dermo-sifiliograficas,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
February 2008,
Nihon rinsho. Japanese journal of clinical medicine,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
March 2018,
American journal of hematology,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
January 2002,
Neurology,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
January 2017,
Internal medicine journal,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
October 2012,
Inflammation & allergy drug targets,
M Moriguchi, and
T Suzuki, and
M Tateishi, and
M Hara, and
S Kashiwazaki
April 2015,
International ophthalmology,
